These findings establish a mechanistic link between BF treatment and EGFR pathway inhibition, demonstrating that BF antagonizes HCC progression by suppressing EGFR-mediated activation of the RAS-RAF-MEK-ERK axis. This evidence concerns the gene EGFR and hepatocellular carcinoma.